Acticor Biotech SAS Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Acticor Biotech SAS.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth	4.6%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Acticor Biotech SAS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ENXTPA:ALACT - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	N/A	-16	N/A	N/A	N/A
3/31/2024	N/A	-18	N/A	N/A	N/A
12/31/2023	N/A	-19	-13	-13	N/A
9/30/2023	N/A	-19	-13	-13	N/A
6/30/2023	N/A	-19	-14	-14	N/A
3/31/2023	N/A	-17	-13	-13	N/A
12/31/2022	N/A	-16	-12	-12	N/A
9/30/2022	N/A	-15	-13	-13	N/A
6/30/2022	N/A	-14	-14	-14	N/A
3/31/2022	N/A	-13	-14	-14	N/A
12/31/2021	N/A	-13	-14	-14	N/A
9/30/2021	N/A	-11	-12	-12	N/A
6/30/2021	N/A	-10	-10	-10	N/A
3/31/2021	N/A	-9	-8	-8	N/A
12/31/2020	N/A	-8	-7	-7	N/A
12/31/2019	N/A	-5	-4	-4	N/A
12/31/2018	0	-6	-6	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ALACT's forecast earnings growth is above the savings rate (1.4%).

Earnings vs Market: Insufficient data to determine if ALACT's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if ALACT's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ALACT's revenue is forecast to grow faster than the French market.

High Growth Revenue: Insufficient data to determine if ALACT's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ALACT's Return on Equity is forecast to be high in 3 years time

Acticor Biotech SAS Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Forecast to breakeven in 2025

No longer forecast to breakeven

Forecast to breakeven in 2023

Recent updates

Acticor Biotech Announces Chief Financial Officer Changes

Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction

Acticor Biotech SAS, Annual General Meeting, Oct 25, 2024

New major risk - Revenue and earnings growth

Acticor Biotech Announces the Conclusions of the Interim Futility Analysis in the Green Study

Acticor Biotech Announces Presentation of the Main Results of the Phase 2/3 Actisave Study in the Treatment of Stroke at ESOC 2024

New minor risk - Financial data availability

Acticor Biotech SAS Announces Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment

Acticor Biotech Will Present the Clinical Results of Its Phase 2/3 Actisave Study in the Treatment of Stroke At Esoc 2024

Acticor Biotech SAS has completed a Follow-on Equity Offering in the amount of €8.031849 million.

Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €7 million.

The University of Birmingham and Acticor Biotech Announce the First Patient Treated in LIBERATE, First Clinical Trial Evaluating Glenzocimab for Heart Attack

Acticor Biotech SAS, Annual General Meeting, Jun 21, 2024

New major risk - Share price stability

Acticor Biotech Announces Publication of ACTIMIS Clinical Study Results in the Lancet Neurology Journal

Acticor Biotech SAS has filed a Follow-on Equity Offering in the amount of €2.55108 million.

Forecast to breakeven in 2025

ACTICOR BIOTECH Announces Timely Completed Patient Recruitment of Its Phase 2/3 Study in Stroke

New minor risk - Share price stability

Acticor Biotech and University of Birmingham Announces The UK Regulatory Agency (MHRA) Approves the Protocol of LIBERATE Study, the First Clinical Trial Evaluating Glenzocimab for Heart Attacks

New minor risk - Profitability

Acticor Biotech SAS Announces the Appointment of Patricia Zilliox to the Board of Directors as an Independent Director

Acticor Biotech SAS Provides an Update on the Progress of Its Clinical Programs with Glenzocimab

Acticor Biotech SAS Provides an Update on the US Regulatory Discussion with the FDA

Acticor Biotech Receives European Medicines Agency Endorsement on Key Parameters of ACTISAVE, Its Pivotal Phase II/III Study for Registration in Stroke

Acticor Biotech SAS to Report Fiscal Year 2022 Results on Mar 29, 2023

Less than half of directors are independent

Acticor Biotech Announces the Enrollment of the First US Patient in its Phase 2/3 Study ACTISAVE for the Treatment of Stroke

Acticor Biotech SAS Receives Priority Medicines Status from the European Medicines Agency for Its Drug Candidate, Glenzocimab

Acticor Biotech SAS Announces Issuance of Patent in Europe for Glenzocimab, Its Innovative Product for the Treatment of Cardiovascular Emergencies

No longer forecast to breakeven

Less than half of directors are independent

Forecast to breakeven in 2023

Acticor Biotech Announces Positive Results from Its ACTIMIS PHASE 1b/2a Study in Patients With Acute Ischemic Stroke (AIS)

Acticor Biotech Announces Results of the Phase 2 Garden Study in Covid-19-Related Acute Respiratory Distress Syndrome

Less than half of directors are independent

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies